Aliases & Classifications for Oligohydramnios

MalaCards integrated aliases for Oligohydramnios:

Name: Oligohydramnios 12 29 54 6 43 15 17 71 32
Oligohydramnios - Delivered 12 71
Oligohydramnios, Antepartum Condition or Complication 71
Antepartum Oligohydramnios 12
Delivered Oligohydramnios 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12215
ICD9CM 34 658.0
MeSH 43 D016104
NCIt 49 C92839
SNOMED-CT 67 59566000
ICD10 32 O41.0
UMLS 71 C0079924 C0157142 C0157143

Summaries for Oligohydramnios

Disease Ontology : 12 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion.

MalaCards based summary : Oligohydramnios, also known as oligohydramnios - delivered, is related to potter's syndrome and renal tubular dysgenesis, and has symptoms including morning sickness An important gene associated with Oligohydramnios is PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin), and among its related pathways/superpathways are Oxytocin signaling pathway and AGE-RAGE signaling pathway in diabetic complications. The drugs Warfarin and Coumarin have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and placenta, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 74 Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. It is the... more...

Related Diseases for Oligohydramnios

Diseases related to Oligohydramnios via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 potter's syndrome 34.3 REN PKHD1 AGT ACE
2 renal tubular dysgenesis 33.7 REN AGTR1 AGT ACE
3 polycystic kidney disease 4 with or without polycystic liver disease 33.2 TMEM67 PKHD1 CC2D2A
4 multiple pterygium syndrome, lethal type 32.6 CHRNG CHRND CHRNA1
5 urinary tract obstruction 31.5 REN AQP1 AGTR1 ACE
6 renal dysplasia 31.4 REN AGTR1 AGT ACE
7 anuria 31.4 REN AGTR1 AGT ACE
8 posterior urethral valves 31.4 AGTR1 AGT ACE
9 polyhydramnios 31.3 REN OXT NPPB EDN1 AQP3 AQP1
10 respiratory failure 31.1 REN NPPB EDN1 ACE
11 pulmonary hypertension 31.1 REN NPPB EDN1 AGTR1 ACE
12 vesicoureteral reflux 1 31.0 REN AGTR1 AGT ACE
13 pre-eclampsia 31.0 REN OXT EDN1 AGTR1 AGT AFP
14 eclampsia 30.9 REN OXT EDN1 AGT ACE
15 diabetes insipidus 30.9 REN OXT AQP3 AFP
16 placenta praevia 30.8 OXT CHRND
17 polycystic kidney disease 30.8 TMEM67 REN PKHD1 EDN1 AQP1 AGTR1
18 placenta disease 30.8 OXT MIR517A AFP
19 end stage renal disease 30.8 REN INF2 AGTR1 AGT ACE
20 microvascular complications of diabetes 3 30.7 REN AGTR1 ACE
21 cystic lymphangioma 30.6 CHRNG CHRND CHRNA1 AFP
22 patent ductus arteriosus 1 30.6 REN NPPB EDN1 ACE
23 kidney disease 30.5 TMEM67 REN PKHD1 NPPB EDN1 AGTR1
24 pulmonary edema 30.2 REN OXT NPPB EDN1 AGTR1 AGT
25 autosomal dominant polycystic kidney disease 30.2 REN PKHD1 EDN1 AQP3 AQP1 AGTR1
26 renal hypodysplasia/aplasia 1 11.5
27 trisomy 2 mosaicism 11.5
28 meckel syndrome, type 1 11.5
29 twin-to-twin transfusion syndrome 11.5
30 severe pre-eclampsia 11.5
31 bilateral renal agenesis dominant type 11.4
32 situs inversus totalis with cystic dysplasia of kidneys and pancreas 11.2
33 urethral obstruction sequence 11.2
34 congenital anomalies of kidney and urinary tract 2 11.1
35 renal dysplasia-limb defects syndrome 11.1
36 meckel syndrome, type 7 11.1
37 fetal indomethacin syndrome 11.1
38 malignant secondary hypertension 10.7 REN AGTR1
39 hypoaldosteronism 10.7 REN ACE
40 renal artery obstruction 10.7 REN ACE
41 microphthalmia, isolated 1 10.7 CHRNG CHRND
42 orthostatic proteinuria 10.7 REN ACE
43 hypertensive encephalopathy 10.7 REN AGTR1 ACE
44 hypertensive retinopathy 10.7 REN AGTR1 ACE
45 hypertension, diastolic 10.7 REN ACE
46 cardiac tuberculosis 10.7 NPPB ACE
47 familial hypertension 10.7 REN AGTR1 AGT
48 polycystic kidney disease 4 10.7 PKHD1 NPPB
49 meningococcal infection 10.6 AGTR1 AGT
50 slow-channel congenital myasthenic syndrome 10.6 CHRND CHRNA1

Graphical network of the top 20 diseases related to Oligohydramnios:



Diseases related to Oligohydramnios

Symptoms & Phenotypes for Oligohydramnios

UMLS symptoms related to Oligohydramnios:


morning sickness

MGI Mouse Phenotypes related to Oligohydramnios:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ACE AFP AGT AGTR1 AQP1 AQP3
2 cardiovascular system MP:0005385 10.13 ACE AGT AGTR1 AQP1 AQP3 CC2D2A
3 growth/size/body region MP:0005378 10.07 ACE AGT AGTR1 AQP1 AQP3 CC2D2A
4 mortality/aging MP:0010768 10.03 ACE AFP AGT AGTR1 AQP1 AQP3
5 nervous system MP:0003631 9.73 AGT AGTR1 AQP1 CC2D2A CHRNA1 CHRNG
6 renal/urinary system MP:0005367 9.36 ACE AGT AGTR1 AQP1 AQP3 CC2D2A

Drugs & Therapeutics for Oligohydramnios

Drugs for Oligohydramnios (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2
Coumarin Experimental Phase 4 91-64-5 323
3 Anticoagulants Phase 4
4 Coagulants Phase 4
5
Oxytocin Approved, Vet_approved Phase 3 50-56-6 53477758 439302
6
Dinoprostone Approved Phase 3 363-24-6 5280360
7
AT-101 Approved, Investigational Phase 2, Phase 3 652-67-5, 90141-22-3 12597
8
Isosorbide Dinitrate Approved, Investigational Phase 2, Phase 3 87-33-2 6883
9
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
10
Enoxaparin Approved Phase 3 9005-49-6 772
11
Dalteparin Approved Phase 3 9005-49-6
12
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
13
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
14 diuretics Phase 2, Phase 3
15 isosorbide-5-mononitrate Phase 2, Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Fibrinolytic Agents Phase 3
18 Acetylsalicylic acid lysinate Phase 3
19 Heparin, Low-Molecular-Weight Phase 3
20 Analgesics Phase 3
21 Antipyretics Phase 3
22 Cyclooxygenase Inhibitors Phase 3
23 Platelet Aggregation Inhibitors Phase 3
24 Antirheumatic Agents Phase 3
25 calcium heparin Phase 3
26 Anti-Inflammatory Agents Phase 3
27 Anti-Inflammatory Agents, Non-Steroidal Phase 3
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
29 Rosuvastatin Calcium Phase 1, Phase 2 147098-20-2
30 Lipid Regulating Agents Phase 1, Phase 2
31 Hypolipidemic Agents Phase 1, Phase 2
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2
33 Anticholesteremic Agents Phase 1, Phase 2
34 Antimetabolites Phase 1, Phase 2
35
Sodium citrate Approved, Investigational 68-04-2
36
Caffeine Approved 58-08-2 2519
37
Misoprostol Approved 59122-46-2 5282381
38
Nifedipine Approved 21829-25-4 4485
39
Indomethacin Approved, Investigational 53-86-1 3715
40
Magnesium Sulfate Approved, Investigational, Vet_approved 7487-88-9 24083
41
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
42
Progesterone Approved, Vet_approved 57-83-0 5994
43
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
44
Vitamin D3 Approved, Nutraceutical 67-97-0 5280795 6221
45
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
46
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
47 Tocotrienol Investigational 6829-55-6
48 Citrate
49 Phosphodiesterase 5 Inhibitors
50 Phosphodiesterase Inhibitors

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
2 a Randomized Clinical Trial Using Oral Anti Coagulant in the Management of Unexplained Oligohydramnios Completed NCT01569035 Phase 4 warfarin
3 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Recruiting NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
4 Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios Unknown status NCT00787163 Phase 3
5 Induction of Labor in Oligohydramnios - A Comparison Between Two Modes of Cervical Ripening for Patients With Oligohydramnios at Term Unknown status NCT00815542 Phase 3 prostaglandins E2
6 Randomized Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Unknown status NCT00127946 Phase 3
7 Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction Unknown status NCT02684305 Phase 3 Administration of Propess;Intravenous oxytocin infusion
8 Nitric Oxide Donors for Treatment of Isolated Oligohydramnios: A Pilot Study Completed NCT02712125 Phase 2, Phase 3 isosorbide mononitrate;Placebo
9 Propess® Versus Double Balloon for Cervical Ripening of Prolonged Pregnancies: a Randomised Controlled Trial Completed NCT02907060 Phase 3 Pharmacological cervical ripening
10 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
11 Inhaled Nitric Oxide For The Treatment Of Hypoxic Respiratory Failure With Pulmonary Hypertension In Preterm Infants Withdrawn NCT00922532 Phase 3 Inhaled Nitric Oxide;Placebo
12 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
13 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
14 Alterations of the Uteroplacental and Fetal Pulmonary Circulation in Patients With Severe Idiopathic Oligohydramnios Following Amnioinfusion Therapy in a Longitudinal Study Unknown status NCT01258725 Phase 1
15 Study to Compare 2 Minimally Invasive Fetal Neural Tube Defect Repair Techniques: Repair Using Durepair Patch vs. Repair Without Durepair Patch Recruiting NCT03794011 Phase 1
16 Minimally Invasive Fetal Neural Tube Defect Repair Study Active, not recruiting NCT02230072 Phase 1
17 Does the Amniotic Fluid Index Affect the Fetal Cardiac Performance? Unknown status NCT03277417
18 Third Trimester Fetal Renal Artery Doppler Indices in Borderline Idiopathic Isolated Oligohydramnios and Relationship Between Neonatal Outcomes Unknown status NCT02901340
19 Sildenafil Citrate Therapy for Oligohydramnios Unknown status NCT02372487 sildenafil citrate
20 Effect of Treatment of Vitamin D Deficiency During Pregnancy on Hypocalcemia Unknown status NCT02021864 vitamin D3 50,000 unit;prenatal multivitamin
21 Randomized Controlled Trial of Amniotic Fluid Index Compared Between After Upright and Left Lateral Decubitus Maternal Position Change Unknown status NCT03536689
22 Clinical Evaluation of PRO-MComplete as an Aid in Determination of Rupture of Fetal Membranes Unknown status NCT02369601
23 Cost-effectiveness of a Screening Strategy for Q Fever Among Pregnant Women in Risk Areas: a Clustered Randomized Controlled Trial Unknown status NCT01095328
24 A Randomized Controlled Study Comparing Cervical Foley Catheter, Vaginal Dinoprostone and a Combination of the Two Methods for Induction of Labor Unknown status NCT02815865 Dinoprostone
25 Open Spina Bifida Fetoscopic Repair Project Unknown status NCT03562286
26 Management of Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term; the Mode of Delivery and the Neonatal Outcomes Completed NCT02581774
27 The Effect of Coffee Consumption on Fetal Renal Artery Blood Flow and Amniotic Fluid Volume in the Third Trimester of Pregnancy Completed NCT03798275
28 Clinical Utility of Uterine, Fetal Cerebral Doppler and Oligohydramnios to Predict Abnormal Heart Rate Tracings in Pregnancies at or Beyond 41 Weeks Completed NCT03703037
29 Perinatal Outcomes According to Amniotic Fluid Indez After Premature Rupture of Membranes. A Prospective Cohort Study. Completed NCT01538030
30 Classification of Fetal Breathing Patterns in the Maturing Upper Airway: Spectral Waveform Analysis of Amniotic Fluid Flow Dynamics in Normal Development, Polyhydramnios, and Oligohydramnios Completed NCT00066976
31 TRANSCERVICAL FOLEY CATHETER (FOLEY) Versus INTRAVAGINAL MISOPROSTOL FOR CERVICAL RIPENING AND INDUCTION OF LABOR: A RANDOMIZED CLINICAL TRIAL. Completed NCT01140971 Misoprostol
32 A Simple Technique to Modify Maternal Uterine Artery Perfusion. Completed NCT01698957
33 Effects of Fetal Movement Counting - a Randomized Controlled Trial of an Unselected Population Completed NCT00513942
34 Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia Completed NCT02015247
35 Comparison Between Fetal Fibronectin (Ffn) vs Cervical Length in Patient With Unfavourable Cervix in Prediction of Successful Induction of Labor Completed NCT03925922
36 A Randomized Clinical Trial on Comparison of Early Versus Late Initiation of Feeding in Preterm Small for Gestation Infants Below 35 Weeks Gestation With Prenatal Absent or Reversal of End Diastolic Flow (AREDF) in Umbilical Artery Completed NCT01759615
37 Are Renal Artery Doppler Indices Different Between Monochorionic Diamniotic Twins With Twin-twin Transfusion Syndrome and Monochorionic Diamniotic Twins Without Twin-twin Transfusion Syndrome? Completed NCT03449823
38 Cervical Ripening With a Double-lumen Balloon Catheter for Six Versus Twelve Hours Completed NCT03086967
39 Tocolysis for Preterm Labor Completed NCT00811057 1 Magnesium Sulfate;Nifedipine;Indomethacin
40 The Pseudo-Oligohydramnios/Hidden Pocket Study: The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index Recruiting NCT03935607
41 Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation: a Randomised Controlled Trial Recruiting NCT04141189
42 Validation of the Standardized Prenatal Clinical Management of Fetuses With Lower Urinary Tract Obstruction (LUTO) Recruiting NCT02315521
43 The Effect of Omega 3 and Vaginal Progesterone on Birth Weight and Doppler Velocimetry of Idiopathic Asymmetrically Intrauterine Growth-restricted Fetuses Recruiting NCT04161989 omega-3 fatty acids;vaginal progesterone
44 Patient Registry for Women Diagnosed With Preterm Premature Rupture of Membranes or PPROM During Pregnancy Recruiting NCT02997345
45 Pulmonary Hypertension in Preterm Children Born at Gestational Age <30 Weeks: Prevalence, Risk Factors and Outcome Recruiting NCT02729844
46 Middle Cerebral and Umbilical Arteries Doppler Indices in Pregestational Diabetic Versus Normal Pregnancies and Their Values in Predicting Adverse Neonatal Outcome Recruiting NCT03915990
47 Renal Anhydramnios Fetal Therapy (RAFT) Trial Recruiting NCT03101891 Isotonic fluid
48 The Influence of Low Sodium Diet on an Amniotic Fluid Index in a Patient That Diagnosed With Oligohydramnios and Assigned for Conservative Management - a Randomized Controlled Trial Not yet recruiting NCT03815968
49 Antenatal and Intrapartum Risk Factors Associated With Neonatal Hypoxic Ischemic Encephalopathy Not yet recruiting NCT04364932
50 Magnetic Resonance Imaging Versus Four Dimensional Ultrasound in Detection of Central Nervous System Fetal Congenital Anomalies Not yet recruiting NCT03888794

Search NIH Clinical Center for Oligohydramnios

Cochrane evidence based reviews: oligohydramnios

Genetic Tests for Oligohydramnios

Genetic tests related to Oligohydramnios:

# Genetic test Affiliating Genes
1 Oligohydramnios 29

Anatomical Context for Oligohydramnios

MalaCards organs/tissues related to Oligohydramnios:

40
Lung, Kidney, Placenta, Heart, Testes, Fetal Lung, Brain

Publications for Oligohydramnios

Articles related to Oligohydramnios:

(show top 50) (show all 2526)
# Title Authors PMID Year
1
The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. 61 54
17653738 2008
2
Abnormal fetal heart rate tracing patterns during the first stage of labor: effect on perinatal outcome. 54 61
11641667 2001
3
[Activity of N-b-D-acetylglucosaminidase molecular forms in amniotic fluid of tobacco smoking pregnant women with oligohydramnios or premature rupture of the membrane complications]. 61 54
10860257 2000
4
Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population. 54 61
9170469 1997
5
Elevated alpha-fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester? 61 54
8750291 1995
6
Maternal serum markers in second-trimester oligohydramnios. 54 61
7526364 1994
7
Origin of raised maternal serum alpha-fetoprotein levels in second-trimester oligohydramnios. 54 61
1372972 1992
8
Amniotic fluid N-acetyl-beta-D-glucosaminidase activity and renal abnormalities. 61 54
1750765 1991
9
[Oligohydramnios in mid-term pregnancy: analysis of 182 cases]. 54 61
2027677 1991
10
Maternal and perinatal outcomes of induction of labor in oligohydramnios at term-a retrospective cohort study. 61
30394156 2020
11
Delivery mode and perinatal outcomes after diagnosis of oligohydramnios at term in China. 61
30486718 2020
12
Clinical predictors of chronic kidney disease in congenital lower urinary tract obstruction. 61
31197474 2020
13
Tübingen hip flexion splints for developmental dysplasia of the hip in infants aged 0-6 months. 61
32503452 2020
14
Utility of ultrasound assessment in management of pregnancies with preterm prelabor rupture of membranes. 61
31332850 2020
15
The impact of residual oligohydramnios following preterm premature rupture of membranes on adverse pregnancy outcomes: a meta-analysis. 61
32109463 2020
16
Pregnancy and delivery in women with a high risk of infection in pregnancy. 61
32576052 2020
17
Aquaporin 1 affects pregnancy outcome and regulates aquaporin 8 and 9 expressions in the placenta. 61
32542408 2020
18
Fetal left ventricular modified myocardial performance index and renal artery pulsatility index in pregnancies with isolated oligohydramnios before 37 weeks of gestation. 61
32517425 2020
19
Perinatal Outcome of Twin Pregnancies Complicated by Rupture of Membranes at 13-20 Weeks: Is Selective Termination an Appropriate Management Option? 61
32542619 2020
20
Prevention of perinatal complications in pregnant women with chronic papillomavirus infection. 61
32564038 2020
21
Perinatal and infant outcome in prenatally diagnosed hyperechogenic kidneys. 61
32530118 2020
22
Neonatal outcome comparisons between preterm infants with or without early pulmonary hypertension following prolonged preterm premature rupture of membranes before 25 gestational weeks in Korean Neonatal Network. 61
32228112 2020
23
[Ultrasonographic manifestation and genetic analysis of a fetus with nephronophthisis type 2]. 61
32335886 2020
24
Induction of labour indications and timing: A systematic analysis of clinical guidelines. 61
31285166 2020
25
Fetal lower urinary tract obstruction: What should we tell the prospective parents? 61
32065667 2020
26
Histologic chorioamnionitis concomitant placental abruption and its effects on pregnancy outcome. 61
32421533 2020
27
Identification of a 6-month-old baby with a combination of WAGR and Potocki-Shaffer contiguous deletion syndromes by SNP array testing. 61
32446308 2020
28
Effect of coffee consumption on fetal renal artery blood flow and amniotic fluid volume in third trimester of pregnancy. 61
32494265 2020
29
False diagnosis of small for gestational age and macrosomia - clinical and sonographic predictors. 61
32429707 2020
30
The effect of fetal weight on the accuracy of sonographic weight estimation among women with diabetes. 61
32441174 2020
31
The changing situation about maternal age, risk factors and pregnancy outcomes after the two-child policy: a retrospective cohort study. 61
32312075 2020
32
Decision-to-delivery interval of emergency cesarean section in Uganda: a retrospective cohort study. 61
32460720 2020
33
Diagnosis of Persistent Cloaca by Ultrasonography and MRI: A Case Report. 61
32381998 2020
34
Does Fetal Pulmonary Venous Flow Impedance Increase in Pregnancies With Placental Insufficiency-Related Oligohydramnios in the Third Trimester? 61
31705722 2020
35
Marginal placental cord insertion: the need for follow up? 61
32397941 2020
36
Fetal umbilical-systemic shunt with a positive issue. 61
31760176 2020
37
Risk factors for perinatal arterial ischaemic stroke: a large case-control study. 61
31489622 2020
38
Notice of Retraction: "Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial" (Maher MA, Sayyed TM, and Elkhouly N). 61
32150003 2020
39
Adverse perinatal outcomes in 665,244 term and post-term deliveries-a Norwegian population-based study. 61
32146227 2020
40
MR imaging of the fetal heart. 61
31190452 2020
41
Rare manifestations of Potter Sequence: A Case Report. 61
32347825 2020
42
Postnatal serum creatinine is elevated in preterm infants with PPROM-induced anhydramnios. 61
32278744 2020
43
Atrial septal aneurysm in pregnancy: echocardiography and obstetric outcomes. 61
32134736 2020
44
The effect of maternal position on fetal middle cerebral artery Doppler indices and its association with adverse perinatal outcomes: a pilot study. 61
32229676 2020
45
Neonatal outcomes following previable prelabour rupture of membranes before 23 weeks of gestation- a retrospective cohort study. 61
32224534 2020
46
Antenatal interventions based upon fetal surveillance of the daily opioid-exposed fetus: a descriptive analysis. 61
30078349 2020
47
A comparison of risk factors for breech presentation in preterm and term labor: a nationwide, population-based case-control study. 61
31741046 2020
48
Value of routine ultrasound examination at 35-37 weeks' gestation in diagnosis of non-cephalic presentation. 61
31671470 2020
49
Altered proteomics profile in the amnion of patients with oligohydramnios. 61
32109340 2020
50
Accuracy of the Ultrasound Estimate of the Amniotic Fluid Volume (Amniotic Fluid Index and Single Deepest Pocket) to Identify Actual Low, Normal, and High Amniotic Fluid Volumes as Determined by Quantile Regression. 61
31423632 2020

Variations for Oligohydramnios

ClinVar genetic disease variations for Oligohydramnios:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CC2D2A NM_001080522.2(CC2D2A):c.1149+1G>ASNV Pathogenic 523401 rs1553827236 4:15518380-15518380 4:15516757-15516757
2 CC2D2A NM_001080522.2(CC2D2A):c.4179+1deldeletion Pathogenic 56312 rs386833760 4:15589552-15589552 4:15587929-15587929
3 46;XY;t(3;18)(q13.31;q22.1)dnTranslocation Pathogenic 268039
4 PKHD1 NM_138694.4(PKHD1):c.107C>T (p.Thr36Met)SNV Pathogenic 4108 rs137852944 6:51947999-51947999 6:52083201-52083201
5 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg)SNV Pathogenic/Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
6 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys)SNV Pathogenic/Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
7 OPHN1 NM_002547.3(OPHN1):c.746T>C (p.Leu249Pro)SNV Likely pathogenic 374192 rs1057518963 X:67430081-67430081 X:68210239-68210239
8 PKHD1 NM_138694.4(PKHD1):c.2716-3C>GSNV Uncertain significance 374193 rs1057518964 6:51908531-51908531 6:52043733-52043733
9 INF2 NM_022489.4(INF2):c.3247A>G (p.Ser1083Gly)SNV Uncertain significance 523532 rs1555375554 14:105180746-105180746 14:104714409-104714409
10 LSM1 NM_014462.3(LSM1):c.231+4A>CSNV Uncertain significance 623485 rs775468919 8:38027316-38027316 8:38169798-38169798

Expression for Oligohydramnios

Search GEO for disease gene expression data for Oligohydramnios.

Pathways for Oligohydramnios

GO Terms for Oligohydramnios

Cellular components related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 SRPX2 REN OXT NPPB EDN1 AGT
2 cytoplasm GO:0005737 9.83 TMEM67 SRPX2 REN PKHD1 OXT NPPB
3 cell GO:0005623 9.7 PKHD1 OXT EDN1 CHRNA1 AQP1 AGTR1
4 MKS complex GO:0036038 9.32 TMEM67 CC2D2A
5 acetylcholine-gated channel complex GO:0005892 8.8 CHRNG CHRND CHRNA1

Biological processes related to Oligohydramnios according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.96 CHRNG CHRND CHRNA1 AQP1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 OXT EDN1 AGTR1 AGT
3 regulation of membrane potential GO:0042391 9.85 CHRNG CHRND CHRNA1
4 kidney development GO:0001822 9.8 REN PKHD1 AGTR1 AGT ACE
5 excitatory postsynaptic potential GO:0060079 9.79 CHRNG CHRND CHRNA1
6 regulation of postsynaptic membrane potential GO:0060078 9.77 CHRNG CHRND CHRNA1
7 nervous system process GO:0050877 9.77 CHRNG CHRND CHRNA1
8 neuromuscular synaptic transmission GO:0007274 9.73 CHRNG CHRND CHRNA1
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.68 AGTR1 AGT
10 vasoconstriction GO:0042310 9.67 EDN1 AGT
11 positive regulation of cellular protein metabolic process GO:0032270 9.67 AGTR1 AGT
12 water transport GO:0006833 9.67 AQP3 AQP1
13 response to nicotine GO:0035094 9.67 EDN1 CHRNG CHRND CHRNA1
14 amyloid-beta metabolic process GO:0050435 9.66 REN ACE
15 positive regulation of urine volume GO:0035810 9.65 NPPB EDN1
16 low-density lipoprotein particle remodeling GO:0034374 9.65 AGTR1 AGT
17 angiotensin maturation GO:0002003 9.65 REN ACE
18 synaptic transmission, cholinergic GO:0007271 9.65 CHRNG CHRND CHRNA1
19 artery smooth muscle contraction GO:0014824 9.64 EDN1 AGT
20 positive regulation of cholesterol esterification GO:0010873 9.64 AGTR1 AGT
21 body fluid secretion GO:0007589 9.63 NPPB EDN1
22 drinking behavior GO:0042756 9.63 REN OXT
23 positive regulation of blood pressure GO:0045777 9.63 OXT AGT ACE
24 glycerol transport GO:0015793 9.62 AQP3 AQP1
25 positive regulation of NAD(P)H oxidase activity GO:0033864 9.61 AGTR1 AGT
26 positive regulation of prostaglandin secretion GO:0032308 9.61 OXT EDN1
27 regulation of blood vessel diameter GO:0097746 9.61 NPPB AGTR1 ACE
28 musculoskeletal movement GO:0050881 9.58 CHRND CHRNA1
29 regulation of renal sodium excretion GO:0035813 9.57 AGTR1 AGT
30 skeletal muscle tissue growth GO:0048630 9.55 CHRND CHRNA1
31 nitric oxide transport GO:0030185 9.54 EDN1 AQP1
32 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.52 AGTR1 AGT
33 regulation of blood volume by renin-angiotensin GO:0002016 9.51 REN AGT
34 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.5 AGTR1 AGT ACE
35 regulation of renal output by angiotensin GO:0002019 9.49 AGT ACE
36 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 AGT ACE
37 renin-angiotensin regulation of aldosterone production GO:0002018 9.43 REN AGTR1 AGT
38 regulation of blood pressure GO:0008217 9.35 REN NPPB EDN1 AGT ACE
39 positive regulation of renal sodium excretion GO:0035815 8.92 OXT NPPB EDN1 AGT

Molecular functions related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.62 OXT NPPB EDN1 AGT
2 neurotransmitter receptor activity GO:0030594 9.61 CHRNG CHRND CHRNA1
3 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNG CHRND CHRNA1
4 channel activity GO:0015267 9.54 CHRNG AQP3 AQP1
5 water channel activity GO:0015250 9.46 AQP3 AQP1
6 acetylcholine binding GO:0042166 9.33 CHRNG CHRND CHRNA1
7 bradykinin receptor binding GO:0031711 9.26 AGTR1 ACE
8 acetylcholine-gated cation-selective channel activity GO:0022848 9.13 CHRNG CHRND CHRNA1
9 acetylcholine receptor activity GO:0015464 8.8 CHRNG CHRND CHRNA1

Sources for Oligohydramnios

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....